| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Licarin A targets multiple pathways involved in inflammation. It inhibits the protein kinase C (PKC) α/βII isoforms and the p38 MAPK pathway. By inhibiting these signaling cascades, licarin A reduces the expression of COX-2 and the secretion of pro-inflammatory mediators such as TNF-α and prostaglandin D2 (PGD2). TNF-α is a key cytokine in the inflammatory response, and its reduction is a major contributor to licarin A's anti-inflammatory effects.
|
|---|---|
| ln Vitro |
Licanoside A is present in plants that are used as spices and traditional medicines to treat digestive and neurological conditions, such as Aristolochia, Runnan, and Myristica. Additionally, licorin A possesses anti-inflammatory properties [1]. Licarin A (5–20 μM) inhibits the p38 MAPK and PKCα/βII pathways to decrease TNF-α and prostaglandin D2 (PGD2) release. Treatment with licorin A tends to lower levels of phosphorylated PKCα/βII and p38 MAPK protein [1].
In vitro, licarin A demonstrates potent anti-inflammatory activity. It inhibits the PKCα/βII and p38 MAPK pathways, leading to a decrease in TNF-α secretion with an IC50 of 12.6 μM. It also reduces the secretion of prostaglandin D2 (PGD2) and the expression of COX-2. These in vitro activities confirm its mechanism of action as an inhibitor of these key inflammatory signaling pathways. |
| ln Vivo |
Detailed in vivo activity data for licarin A are not extensively provided in the search results. However, its anti-inflammatory properties suggest potential for in vivo efficacy in models of inflammation. Its presence in plants used in folk medicines for various disorders also hints at its therapeutic potential. Further in vivo studies would be required to fully characterize its efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
Non-cell-based assays for licarin A would typically involve enzyme inhibition assays for its targets. For PKCα/βII, the enzyme would be incubated with a substrate and ATP, and licarin A would be added at various concentrations. The kinase activity would be measured, and an IC50 would be determined. For p38 MAPK, a similar kinase assay would be used.
|
| Cell Assay |
Cellular assays for licarin A are performed using immune cells such as macrophages. The cells are stimulated with LPS to induce an inflammatory response. Licarin A is added at various concentrations, and the levels of TNF-α and PGD2 in the culture supernatant are measured by ELISA. The expression of COX-2 is measured by Western blotting or qPCR. These assays confirm the compound's anti-inflammatory activity.
|
| Animal Protocol |
In vivo animal models for licarin A would likely involve standard models of inflammation, such as the carrageenan-induced paw edema model in rats or the LPS-induced sepsis model in mice. The compound would be administered, and inflammatory markers and tissue damage would be assessed. These studies are essential for evaluating the compound's therapeutic potential.
|
| ADME/Pharmacokinetics |
Licarin A has a molecular weight of 326.15 g/mol and a molecular formula of C20H22O4. It is a lipophilic compound that is soluble in DMSO and other organic solvents. Detailed PK parameters such as half-life and bioavailability are not extensively detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for licarin A are not provided in the search results. As a natural product, it is generally considered to have a good safety profile, but thorough toxicological studies would be required for therapeutic development. The compound is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
(-)-Licarin A has been reported to be found in plants of the genera Aristolochia fordiana, Jackiella javanica, and other organisms with available data.
Licarin A is a natural neolignan with anti-inflammatory properties. It inhibits PKCα/βII and p38 MAPK pathways, decreasing TNF-α secretion (IC50 = 12.6 μM) and PGD2 secretion, as well as COX-2 expression. It is found in licorice and other plants and has the CAS number 51020-86-1. It is supplied for research purposes as a natural product standard. |
| Molecular Formula |
C20H22O4
|
|---|---|
| Molecular Weight |
326.39
|
| Exact Mass |
326.151
|
| CAS # |
51020-86-1
|
| Related CAS # |
83377-50-8 (rotation +);51020-86-1 (rotation -);
|
| PubChem CID |
6442393
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
452.0±45.0 °C at 760 mmHg
|
| Flash Point |
227.2±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.596
|
| LogP |
4.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C/C=C/C1=CC2=C(C(=C1)OC)O[C@@H]([C@H]2C)C3=CC(=C(C=C3)O)OC
|
| InChi Key |
ITDOFWOJEDZPCF-FNINDUDTSA-N
|
| InChi Code |
InChI=1S/C20H22O4/c1-5-6-13-9-15-12(2)19(24-20(15)18(10-13)23-4)14-7-8-16(21)17(11-14)22-3/h5-12,19,21H,1-4H3/b6-5+/t12-,19-/m0/s1
|
| Chemical Name |
2-methoxy-4-[(2S,3S)-7-methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydro-1-benzofuran-2-yl]phenol
|
| Synonyms |
NSC-370989; NSC 370989; Licarin A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~153.19 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0638 mL | 15.3191 mL | 30.6382 mL | |
| 5 mM | 0.6128 mL | 3.0638 mL | 6.1276 mL | |
| 10 mM | 0.3064 mL | 1.5319 mL | 3.0638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
